AboutMesothelioma.Net

According to the May 6th Journal of the National Cancer institute, a 4-gene expression ratio test accurately predicts survival in patients with malignant pleural mesothelioma.

The study performed by researchers from the Brigham and Women’s Hospital, involved 120 patients undergoing surgery for malignant pleural mesothelioma. Multiple samples were gathered either during surgery or through pleural biopsy. Researchers evaluated the test on multiple tumor samples from each patient and used two different gene samples and two different biopsy techniques.

The results were adjusted for other clinical factors and coupled with other mesothelioma prognosis information and patients were categorized into two groups. Patients assigned by the test to the good outcome group had significantly better median overall survival, 31.9 months, compared to the poor outcome group, 6.9 months.

It is hoped that this test will help doctors better determine a prognosis for patients. Patients who have a shorter life-expectancy can be counseled away from surgeries that would not benefit them or their families and allow them time seek hospice or other supportive care. For patients with a higher expectancy, doctors could help them to arrange for more long term treatments and surgeries.

Additional information about mesothelioma research and ongoing studies may be found at Mesothelioma Help.net.